Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ejaculatory dysfunction after retroperitoneal lymphadenectomy

D R Jones1, A R Norman, A Horwich

  • 1Testicular Tumour Unit, Royal Marsden Hospital, London, UK.

European Urology
|January 1, 1993
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees†.

Annals of oncology : official journal of the European Society for Medical Oncology·2019
Same author

Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†.

Annals of oncology : official journal of the European Society for Medical Oncology·2019
Same author

ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-up.

Annals of oncology : official journal of the European Society for Medical Oncology·2018
Same author

Enantioselective total synthesis and biological evaluation of (-)-solanacol.

Organic & biomolecular chemistry·2018
Same author

Appendix 9: Testicular seminoma and non-seminoma: eUpdate published online 29 June 2017 (www.esmo.org/Guidelines/Genitourinary-Cancers).

Annals of oncology : official journal of the European Society for Medical Oncology·2017
Same author

appendix 8: Prostate cancer: eUpdate published online September 2016 (http://www.esmo.org/Guidelines/Genitourinary-Cancers).

Annals of oncology : official journal of the European Society for Medical Oncology·2016
Same journal

Diagnosis and Staging of Patients with Prostate Cancer: Report from the 2025 Advanced Prostate Cancer Consensus Conference (APCCC) Diagnostics.

European urology·2026
Same journal

Re: Twelve-month Results from the CISTO Study Comparing Radical Cystectomy Versus Bladder-sparing Therapy for Recurrent High-grade Non-muscle-invasive Bladder Cancer: Recurrent High-risk NMIBC: One Bladder, Choose Wisely.

European urology·2026
Same journal

Re: Dries Develtere, Riccardo Bertolo. Cumulative Genitourinary Toxicity After Prostate Radiotherapy: High-Level Long-Term Randomized Evidence. J Clin Oncol. Online ahead of print. http://dx.doi.org/10.1200/JCO-26-00436.

European urology·2026
Same journal

In Memory of Paul Mitrofanoff (1934-2025).

European urology·2026
Same journal

Re: McKay RR, Pal S, Xie W, et al. Advanced Urologic Cancer Consensus Conference (AUC3) 2025: Expert Consensus on the Management of Renal Cell and Urinary Tract Cancers. CA Cancer J Clin 2026;76:e70052.

European urology·2026
Same journal

Re: Ultra-hypofractionated Stereotactic Ablative Body Radiotherapy for Primary Renal Cell Carcinoma: 5-year Outcomes from a Pooled Analysis of the FASTRACK Trials.

European urology·2026
See all related articles

Retroperitoneal lymphadenectomy can cause permanent ejaculation loss in testicular cancer survivors. Nerve-sparing techniques and smaller residual masses significantly reduce this risk.

Area of Science:

  • Urology
  • Oncology
  • Reproductive Medicine

Background:

  • Metastatic non-seminomatous germ cell tumors often require retroperitoneal lymphadenectomy (RPL) after chemotherapy.
  • Ejaculatory dysfunction is a known complication of RPL.

Purpose of the Study:

  • To evaluate the impact of retroperitoneal lymphadenectomy on ejaculation in patients with residual masses.
  • To identify factors influencing postoperative ejaculatory dysfunction.

Main Methods:

  • Analysis of 186 patients undergoing RPL for residual masses post-chemotherapy.
  • Statistical analysis using chi-squared test of independence to assess significance.
  • Comparison of outcomes before and after the introduction of nerve-sparing dissection.

Related Experiment Videos

Main Results:

  • 22% of patients experienced permanent ejaculatory loss.
  • Larger residual mass size (>8 cm) significantly increased risk (58% vs. 4% for <4 cm).
  • Bilateral mass removal (45%) was associated with higher dysfunction rates than unilateral (12%).
  • Nerve-sparing dissection reduced dysfunction from 36% to 16% post-1984.

Conclusions:

  • Residual mass characteristics (size, laterality) and surgical technique significantly impact ejaculatory function post-RPL.
  • Nerve-sparing retroperitoneal lymphadenectomy is crucial for minimizing ejaculatory dysfunction in testicular cancer patients.
  • Patient counseling regarding potential ejaculatory dysfunction should consider mass characteristics.